Patricia T Greipp

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5046547/publications.pdf

Version: 2024-02-01

168 papers	3,042 citations	159585 30 h-index	197818 49 g-index
169 all docs	169 docs citations	169 times ranked	4637 citing authors

#	Article	IF	Citations
1	Comparative study of therapyâ€related and de novo adult bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2022, 196, 963-968.	2.5	6
2	BRAF Rearrangements and BRAF V600E Mutations Are Seen in a Subset of Pancreatic Carcinomas With Acinar Differentiation. Archives of Pathology and Laboratory Medicine, 2022, 146, 840-845.	2.5	5
3	Detection of a Cryptic KMT2A/AFDN Gene Fusion [ins(6;11)(q27;q23q23)] in a Pediatric Patient with Newly Diagnosed Acute Myeloid Leukemia. Laboratory Medicine, 2022, 53, e95-e99.	1.2	1
4	Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series. Blood Cancer Journal, 2022, 12, 11.	6.2	9
5	A Novel USP25::PDGFRA Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm. Laboratory Medicine, 2022, 53, e134-e138.	1.2	1
6	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	6.2	30
7	Gene fusions in gastrointestinal tract cancers. Genes Chromosomes and Cancer, 2022, 61, 285-297.	2.8	4
8	Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature. Annals of Diagnostic Pathology, 2022, 58, 151942.	1.3	1
9	BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers. Ocular Oncology and Pathology, 2022, 8, 22-29.	1.0	0
10	Apparent coexistence of ETV6::RUNX1 and KMT2A::MLLT3 fusions due to a nonproductive KMT2A rearrangement in B-ALL. Leukemia and Lymphoma, 2022, , 1-4.	1.3	1
11	CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma. Cancers, 2022, 14, 2299.	3.7	6
12	Outcomes following venetoclaxâ€based treatment in therapyâ€related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	4.1	7
13	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. Blood Cancer Journal, 2022, 12, .	6.2	6
14	Spurious <scp>CD34</scp> expression in Bâ€cell lymphoma due to nonspecific binding to <scp>PerCPâ€Cy5</scp>.5 fluorochrome conjugates: A rare phenomenon and a diagnostic pitfall. Cytometry Part B - Clinical Cytometry, 2022, 102, 326-328.	1.5	3
15	Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dualâ€color dualâ€fusion FISH studies. Genes Chromosomes and Cancer, 2022, 61, 629-634.	2.8	7
16	Mediastinal B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements. Journal of Hematopathology, 2022, 15, 151-155.	0.4	2
17	Novel t(1;8)(p31.3;q21.3) NFIA-RUNX1T1 Translocation in an Infant Erythroblastic Sarcoma. American Journal of Clinical Pathology, 2021, 156, 129-138.	0.7	10
18	Detection of a Cryptic EP300/ZNF384 Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia. Laboratory Medicine, 2021, 52, 297-302.	1.2	0

#	Article	IF	Citations
19	Identification of a novel <scp>KMT2A</scp>/<scp>GIMAP8</scp> gene fusion in a pediatric patient with acute undifferentiated leukemia. Genes Chromosomes and Cancer, 2021, 60, 108-111.	2.8	5
20	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular Therapy, 2021, 27, 165.e1-165.e11.	1.2	11
21	Erythroblastic sarcoma transformation from a chronic myeloid neoplasm with FGFR1 rearrangement presenting as a pleural effusion: a case report. Journal of Hematopathology, 2021, 14, 157-162.	0.4	0
22	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. Blood Cancer Journal, 2021, 11, 18.	6.2	8
23	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. Cancer Research, 2021, 81, 3333-3346.	0.9	16
24	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
25	Adult Philadelphia-like B-cell acute lymphoblastic leukemia: Characteristics, outcomes, and role of allogeneic hematopoietic cell transplantation in comparison to Philadelphia-positive and Philadelphia-negative acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2021, 39, 7022-7022.	1.6	2
26	Assessment of fixedâ€duration therapies for treatmentâ€naÃ¯ve <scp>WaldenstrÃ¶m</scp> macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	4.1	12
27	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	6.2	7
28	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. Genes Chromosomes and Cancer, 2021, 60, 678-686.	2.8	2
29	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. Human Pathology, 2021, 112, 20-34.	2.0	19
30	The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Clinical Cancer Research, 2021, 27, 5430-5439.	7.0	14
31	Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. Annals of Diagnostic Pathology, 2021, 53, 151761.	1.3	8
32	Disease outcomes and biomarkers of progression in smouldering WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	2.5	12
33	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISHâ€based algorithm distinguishes prognostic groups and outcomes. Blood Cancer Journal, 2021, 11, 156.	6.2	4
34	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e710-e713.	0.4	0
35	OUP accepted manuscript. Laboratory Medicine, 2021, , .	1.2	1
36	Prognostic significance of acquired 1q22 gain in multiple myeloma. American Journal of Hematology, 2021, , .	4.1	6

#	Article	IF	Citations
37	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFRA gene fusions. Cancer Genetics, 2021, 260-261, 1-5.	0.4	0
38	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. Blood Cancer Journal, 2021, 11, 184.	6.2	6
39	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
40	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. Blood, 2021, 138, 3771-3771.	1.4	1
41	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). Blood, 2021, 138, 2285-2285.	1.4	0
42	False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias. Blood, 2021, 138, 4101-4101.	1.4	0
43	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. Blood, 2021, 138, 3691-3691.	1.4	1
44	Fluorescence inâ€ŝitu hybridisation for TP63 rearrangements in T cell lymphomas: singleâ€ŝite experience of 470 patients and implications for clinical testing. Histopathology, 2020, 76, 481-485.	2.9	8
45	Ibrutinib monotherapy outside of clinical trial setting in WaldenstrÃ¶m macroglobulinaemia: practice patterns, toxicities and outcomes. British Journal of Haematology, 2020, 188, 394-403.	2.5	41
46	Clinical utility of fluorescence in situ hybridizationâ€ŝbased diagnosis of BCRâ€ABL1 like (<scp>P</scp>hiladelphia chromosome like) <scp>B</scp>â€ŝcute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	4.1	4
47	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. Cancer Genetics, 2020, 241, 67-71.	0.4	3
48	Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies. Leukemia and Lymphoma, 2020, 61, 975-978.	1.3	7
49	Impact of MYD88^{L265P} mutation status on histological transformation of WaldenstrÃ¶m Macroglobulinemia. American Journal of Hematology, 2020, 95, 274-281.	4.1	33
50	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2020, 34, 1373-1382.	7.2	40
51	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 6581-6588.	7.0	32
52	Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. Annals of Diagnostic Pathology, 2020, 48, 151588.	1.3	1
53	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Advances, 2020, 4, 3509-3519.	5.2	58
54	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer Journal, 2020, 10, 82.	6.2	59

#	Article	IF	Citations
55	Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. Annals of Diagnostic Pathology, 2020, 46, 151533.	1.3	8
56	Twin-to-twin transmission of transient abnormal myelopoiesis without constitutional trisomy 21: A case report. Cancer Genetics, 2020, 244, 62-64.	0.4	1
57	Rare MDM2 amplification in a fat-predominant angiomyolipoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 661-666.	2.8	1
58	Characteristics of patients with myelodysplastic syndrome with balanced translocations. British Journal of Haematology, 2020, 190, 244-248.	2.5	1
59	Systematic use of fluorescence inâ€situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. Histopathology, 2020, 76, 1042-1054.	2.9	13
60	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Annals of Hematology, 2020, 99, 513-518.	1.8	1
61	Case Report with Review of the Literature: Uveal Melanoma in a Patient with Carney Complex â€“ Another Rare Component of the Syndrome?. Ocular Oncology and Pathology, 2020, 6, 311-317.	1.0	2
62	Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Head and Neck Pathology, 2020, 14, 951-965.	2.6	11
63	Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. Cancer Genetics, 2020, 243, 48-51.	0.4	6
64	Cryptic and atypical <scp>KMT2Aâ€USP2</scp> and <scp>KMT2Aâ€USP8</scp> rearrangements identified by mate pair sequencing in infant and childhood leukemia. Genes Chromosomes and Cancer, 2020, 59, 422-427.	2.8	7
65	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Advances, 2020, 4, 2236-2244.	5.2	20
66	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. Blood, 2020, 136, 9-10.	1.4	0
67	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. Blood, 2020, 136, 26-27.	1.4	1
68	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. Blood, 2020, 136, 44-44.	1.4	0
69	Heterogeneity of MYC Abnormalities in Multiple Myeloma. Blood, 2020, 136, 2-3.	1.4	0
70	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. Blood, 2020, 136, 21-22.	1.4	0
71	HepaticYAP1-TFE3Rearranged Epithelioid Hemangioendothelioma. Case Reports in Gastrointestinal Medicine, 2019, 2019, 1-5.	0.3	5
72	Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma. Mayo Clinic Proceedings, 2019, 94, 1381-1384.	3.0	7

#	Article	IF	Citations
73	Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. Journal of Hematology and Oncology, 2019, 12, 73.	17.0	71
74	Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: AÂCase of Unrecognized t(2;11) Structural Variation. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 598-602.	0.4	2
75	Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. Cancer Genetics, 2019, 237, 51-54.	0.4	5
76	Characterization of TCF3 rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel TCF3/TEF gene fusion. Blood Cancer Journal, 2019, 9, 81.	6.2	14
77	Atypical lipomatous tumour/wellâ€differentiated liposarcoma and deâ€differentiated liposarcoma in patients agedÂâ‰Â40Âyears: a study of 116 patients. Histopathology, 2019, 75, 833-842.	2.9	16
78	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal, 2019, 9, 73.	6.2	37
79	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. American Journal of Hematology, 2019, 94, E117-E120.	4.1	13
80	Aurora kinase B-phosphorylated HP1Î± functions in chromosomal instability. Cell Cycle, 2019, 18, 1407-1421.	2.6	7
81	Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes. Journal of Hematopathology, 2019, 12, 85-90.	0.4	0
82	Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia. Journal of Hematopathology, 2019, 12, 99-104.	0.4	1
83	Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements. Journal of Physical Education and Sports Management, 2019, 5, a004077.	1.2	14
84	Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. Human Pathology, 2019, 87, 65-74.	2.0	41
85	Natural history of multiple myeloma with de novo del(17p). Blood Cancer Journal, 2019, 9, 32.	6.2	38
86	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer Journal, 2019, 9, 20.	6.2	10
87	Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. Journal of Physical Education and Sports Management, 2019, 5, a003533.	1.2	8
88	A nearâ€haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed Bâ€lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 665-668.	2.8	3
89	Acute leukemias harboring KMT2A/MLLT10 fusion: a 10â€year experience from a single genomics laboratory. Genes Chromosomes and Cancer, 2019, 58, 567-577.	2.8	19
90	Impact of acquired del(17p) in multiple myeloma. Blood Advances, 2019, 3, 1930-1938.	5.2	41

#	Article	IF	Citations
91	Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Advances, 2019, 3, 1298-1302.	5.2	16
92	Mate pair sequencing outperforms fluorescence in situ hybridization and improves diagnostic yield in the genomic characterization of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e58.	0.4	0
93	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. Blood Cancer Journal, 2019, 9, 103.	6.2	27
94	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	4.1	11
95	Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer. Mayo Clinic Proceedings, 2019, 94, 27-36.	3.0	7
96	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. Leukemia and Lymphoma, 2019, 60, 821-824.	1.3	2
97	False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms. Haematologica, 2019, 104, e248-e251.	3.5	43
98	Constitutional chromosome rearrangements that mimic the 2017 world health organization â€œacute myeloid leukemia with recurrent genetic abnormalitiesâ€: A study of three cases and review of the literature. Cancer Genetics, 2019, 230, 37-46.	0.4	8
99	Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. Human Pathology, 2019, 89, 109-114.	2.0	7
100	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leukemia and Lymphoma, 2019, 60, 990-999.	1.3	9
101	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. European Journal of Haematology, 2019, 102, 87-96.	2.2	35
102	Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large national reference laboratory.. Journal of Clinical Oncology, 2019, 37, 3144-3144.	1.6	0
103	Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype. Blood, 2019, 134, 5210-5210.	1.4	0
104	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. Blood, 2019, 134, 2588-2588.	1.4	0
105	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. Blood, 2019, 134, 1800-1800.	1.4	1
106	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	7.2	28
107	De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. Modern Pathology, 2018, 31, 705-717.	5.5	25
108	Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood, 2018, 131, 2262-2266.	1.4	77

#	Article	IF	Citations
109	Polypoid fibroadipose tumors of the esophagus: â€˜giant fibrovascular polypâ€™ or liposarcoma? A clinicopathological and molecular cytogenetic study of 13 cases. Modern Pathology, 2018, 31, 337-342.	5.5	37
110	Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. Modern Pathology, 2018, 31, 141-149.	5.5	47
111	Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1â€PRKACA fusion. Hepatology, 2018, 68, 1441-1447.	7.3	48
112	Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma. American Journal of Surgical Pathology, 2018, 42, 256-263.	3.7	34
113	PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. International Journal of Gynecological Pathology, 2018, 37, 537-546.	1.4	9
114	A 10-Year Review of KMT2A Gene Fusion Partners Observed in Pediatric T-Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience. American Journal of Clinical Pathology, 2018, 150, S132-S132.	0.7	0
115	Use of Mate-Pair Sequencing (MPseq) to Elucidate a Complex BCR-ABL1 Rearrangement Observed in a Newly Diagnosed Case of Chronic Myeloid Leukemia. American Journal of Clinical Pathology, 2018, 150, S131-S132.	0.7	0
116	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal, 2018, 8, 97.	6.2	36
117	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. Cancer Genetics, 2018, 228-229, 197-217.	0.4	25
118	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E398-E401.	4.1	1
119	KMT2A (MLL) rearrangements observed in pediatric/young adult Tâ€lymphoblastic leukemia/lymphoma: A 10â€year review from a single cytogenetic laboratory. Genes Chromosomes and Cancer, 2018, 57, 541-546.	2.8	21
120	14. Clinical mate-pair sequencing reveals complex genomic rearrangements in B-lymphoblastic leukemia/lymphoma (B-ALL). Cancer Genetics, 2018, 224-225, 55-56.	0.4	0
121	Defining Lymphoplasmacytic Lymphoma. American Journal of Clinical Pathology, 2018, 150, 168-176.	0.7	5
122	12. Mate pair sequencing: Unveiling underappreciated complexity and providing clarity to the previously unanswered questions of cytogenetics. Cancer Genetics, 2018, 224-225, 54-55.	0.4	0
123	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. American Journal of Clinical Pathology, 2018, 150, 421-431.	0.7	12
124	The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms. American Journal of Clinical Pathology, 2018, 150, 375-384.	0.7	13
125	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. American Journal of Hematology, 2018, 93, E355-E357.	4.1	2
126	13. Clinical utility of mate pair sequencing to detect diagnostic and prognostic chromosomal rearrangements and copy number changes in patients with acute myeloid leukemia. Cancer Genetics, 2018, 224-225, 55.	0.4	0

#	Article	IF	Citations
127	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. Blood, 2018, 132, 4460-4460.	1.4	1
128	The impact of clonal size on the revised international prognostic scoring system (R-IPSS) in myelodysplastic syndromes (MDS) with a single cytogenetic abnormality.. Journal of Clinical Oncology, 2018, 36, 7068-7068.	1.6	0
129	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome per 2017 WHO guideline compared to de novo MDS.. Journal of Clinical Oncology, 2018, 36, e19026-e19026.	1.6	0
130	Abstract 655: Hyperdiploidy in plasma cell disorders using multi-parametric flow cytometry (MFC) vs. FISH. , 2018, , .		0
131	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. Blood, 2018, 132, 5510-5510.	1.4	0
132	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. Blood, 2018, 132, 4449-4449.	1.4	0
133	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2884-2884.	1.4	1
134	Loss of p16 INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas. Journal of Thoracic Oncology, 2017, 12, 860-871.	1.1	28
135	Environmental exposures as a risk factor for fibrolamellar carcinoma. Modern Pathology, 2017, 30, 892-896.	5.5	7
136	Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival. Biology of Blood and Marrow Transplantation, 2017, 23, 782-789.	2.0	7
137	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, 2017, 129, 3419-3427.	1.4	335
138	Diagnosis and Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2017, 3, 1257.	7.1	110
139	Gastroblastoma harbors a recurrent somatic MALAT1â€“GLI1 fusion gene. Modern Pathology, 2017, 30, 1443-1452.	5.5	93
140	Outcome of patients younger than 50 years old diagnosed with myelodysplastic syndromes (MDS): Single institution experience.. Journal of Clinical Oncology, 2017, 35, e18560-e18560.	1.6	0
141	<scp>FGFR</scp>1 and <scp>FGFR</scp>2 in fibrolamellar carcinoma. Histopathology, 2016, 68, 686-692.	2.9	12
142	BCRâ€“JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. Cancer Genetics, 2016, 209, 223-228.	0.4	19
143	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Letters, 2016, 380, 163-173.	7.2	72
144	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood, 2016, 128, 1234-1245.	1.4	105

#	Article	IF	Citations
145	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May HarborMYD88L265P Mutations. American Journal of Clinical Pathology, 2016, 145, 843-851.	0.7	43
146	Clinical utility of myb rearrangement detection and p63/p40 immunophenotyping in the diagnosis of adenoid cystic carcinoma of minor salivary glands: a pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 282-289.	0.4	21
147	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. Blood, 2016, 128, 5541-5541.	1.4	0
148	Utilization of Mate-Pair Sequencing to Characterize Complex and Novel TCF3 Translocations. Blood, 2016, 128, 4086-4086.	1.4	0
149	Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma. Journal of Thoracic Oncology, 2015, 10, 1570-1575.	1.1	40
150	Ovarian Hemangiomas Do Not Harbor EWSR1 Rearrangements. International Journal of Gynecological Pathology, 2015, 34, 437-444.	1.4	7
151	Analysis of MDM2 Amplification in 43 Endometrial Stromal Tumors. International Journal of Gynecological Pathology, 2015, 34, 576-583.	1.4	33
152	DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Modern Pathology, 2015, 28, 822-829.	5.5	142
153	Brain Metastasis of Crystal-Deficient, CD68-Positive Alveolar Soft Part Sarcoma: Ultrastructural Features and Differential Diagnosis. Ultrastructural Pathology, 2015, 39, 69-77.	0.9	8
154	Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. Modern Pathology, 2014, 27, 113-127.	5.5	65
155	Secondary Philadelphia chromosome and erythrophagocytosis in a relapsed acute myeloid leukemia after hematopoietic cell transplantation. Cancer Genetics, 2014, 207, 268-271.	0.4	5
156	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. British Journal of Haematology, 2013, 163, 326-333.	2.5	35
157	Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders with Biallelic Rearrangements of DUSP22. Journal of Investigative Dermatology, 2013, 133, 1680-1682.	0.7	17
158	Very High Risk CLL Characterized by a â€œDouble Hitâ€•Clone with Both 11q22 and 17p13 Deletion.. Blood, 2012, 120, 2486-2486.	1.4	0
159	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,. Blood, 2011, 118, 3538-3538.	1.4	16
160	Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience. Mayo Clinic Proceedings, 2010, 85, 905-912.	3.0	137
161	FISH Redoux â€" A Novel Way to Emulate CLL Leukemic Cells From Buffy Coat Samples. Blood, 2010, 116, 3606-3606.	1.4	0
162	Isolated Trisomy 8 in the Myelodysplastic Syndromes.. Blood, 2009, 114, 2785-2785.	1.4	0

#	Article	IF	Citations
163	Whole Arm Duplication of 1q in Myeloid Neoplasm, with Emphasis On Derivative (1;7)(q10;p10).. Blood, 2009, 114, 4238-4238.	1.4	1
164	Antiâ€CD20 monoclonal antibody therapy in multiple myeloma. British Journal of Haematology, 2008, 141, 135-148.	2.5	98
165	In-111DAC Is a Novel Technique To Image Multiple Myeloma.. Blood, 2006, 108, 3488-3488.	1.4	1
166	Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab.. Blood, 2005, 106, 5178-5178.	1.4	0
167	Prevalence, breakpoint distribution, and clinical correlates of t(5;12). Cancer Genetics and Cytogenetics, 2004, 153, 170-172.	1.0	31
168	Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma.. Blood, 2004, 104, 3649-3649.	1.4	2